Jaguar Health, Inc. (JAGX)
NASDAQ: JAGX · Real-Time Price · USD
0.241
-0.039 (-13.96%)
At close: Apr 28, 2026, 4:00 PM EDT
0.240
-0.001 (-0.37%)
After-hours: Apr 28, 2026, 7:47 PM EDT
Jaguar Health Employees
Jaguar Health had 47 employees as of December 31, 2025. The number of employees decreased by 2 or -4.08% compared to the previous year.
Employees
47
Change (1Y)
-2
Growth (1Y)
-4.08%
Revenue / Employee
$244,915
Profits / Employee
-$1,139,894
Market Cap
3.38M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| CollPlant Biotechnologies | 39 |
| PMGC Holdings | 34 |
| Aptevo Therapeutics | 33 |
| Cardio Diagnostics Holdings | 17 |
| BioRestorative Therapies | 14 |
| Dermata Therapeutics | 9 |
| Ernexa Therapeutics | 7 |
| Mustang Bio | 4 |
JAGX News
- 1 day ago - Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split - Accesswire
- 4 days ago - Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) - Accesswire
- 8 days ago - Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders - Accesswire
- 15 days ago - Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs - Accesswire
- 18 days ago - Jaguar Health Earnings Call Transcript: Q4 2025 - Transcripts
- 19 days ago - Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates - Accesswire
- 20 days ago - Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs - Accesswire
- 21 days ago - Jaguar Health Reports 2025 Financials - Accesswire